Modulation of mitogen-activated protein kinases by 6-nitro-7- hydroxycoumarin mediates apoptosis in renal carcinoma cells

European Journal of Pharmacology

Volumn 481, Issue 2-3, 2003, Pages 159-167

  Finn, Gregory ^a   Creaven, Bernadette ^a   Egan, Denise ^a  

^a DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

Author keywords

6 Nitro 7 hydroxycoumarin; Apoptosis; Cell cycle; p38 MAP kinase; Renal cell carcinoma

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 NITRO 7 HYDROXYCOUMARIN; ADENOSINE DIPHOSPHATE RIBOSE; ANTINEOPLASTIC AGENT; COUMARIN DERIVATIVE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN P21; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL STRUCTURE; CONTROLLED STUDY; DIPLOIDY; DNA CLEAVAGE; ENZYME DEGRADATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0344827168     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.09.035     Document Type: Article

References (47)

1. Adler V., Yin Z., Fuchs S.Y., Berenza M., Rosario L., Tew K.D., Pincus M.R., Saranda M., Heredeson C.J., Wolf C.R., Davis R.J., Ronai Z. Regulation of JNK signalling. EMBO J. 18:1999;1321-1334.
2. Barnes C.J., Bagheri-Yarmand R. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol. Cancer Ther. 2:2003;345-351.
3. Bartkova J., Lukas J., Bartek J. Abberations of the G1 and G1/S regulating genes in human cancer. Prog. Cell Cycle Res. 3:1997;211-220.
4. Blatt N.B., Glinck G.D. Signaling pathways and effector mechanisms preprogrammed cell death. Bioorg. Med. Chem. 9:2001;1371-1384.
5. Bourbon N.A., Yun J., Kester M. Ceramide directly activates protein kinase C to regulate a stress-activated protein kinase signalling complex. J. Biol. Chem. 275:2000;35617-35623.
6. Broghammer E.L., Ratliff T.L. Immunotherapy of urological tumours: principles and progress. Urol. Oncol. 7:2002;45-56.
7. Casley-Smith J.R., Casley-Smith J.R. Coumarins. O'Kennedy R., Thornes R.D. Biology, Applications and Mode of Action. 1997;148-185 Wiley, Chichester, England.
8. Chan H.C., Kuo S.C., Huang L.J., Liu C.H., Hsu S.L. A phenylacetate derivative, SCK6, inhibits cell proliferation via G(1) cell cycle arrest and apoptosis. Eur. J. Pharmacol. 467:2003;31-39.
9. Chu C.C., Tsai Y., Lin W., Tseng T. Induction of apoptosis by esculetin in human leukemia cells. Eur. J. Pharmacol. 416:2001;25-32.
10. Cobb M.H. MAP kinase pathways. Prog. Biophys. Mol. Biol. 71:1999;479-500.
11. Conley D., Marshall E.M. Effects of coumarin on human tumour cell growth and cell cycle analysis in vitro. Proc. Am. Assoc. Cancer Res. 28:1987;63.
12. Cross T.G., Scheel-Toellner D., Henrequiz N.V., Deacon E., Salmon M., Lord J.M. Serine/threnoine protein kinases and apoptosis. Exp. Cell Res. 256:2000;34-41.
13. Darzynkiewicz Z., Bedner E., Smolewski P. Flow cytometry in analysis of cell cycle and apoptosis. Semin. Hematol. 38:2001;179-193.
14. Egan D.A., Cox D., O'Kennedy R., Moran E., Prosser E., Thornes R.D. The pharmacology, metabolism, analysis and applications of coumarin and coumarin related compounds. Drug Metab. Rev. 22:1990;503-529.
15. Egan D., James P., Cooke D., O'Kennedy R. Studies on the cytostatic and cytotoxic effects and mode of action of 8-nitro-7-hydroxycoumarin. Cancer Lett. 118:1997;201-211.
16. Engelman J.A. Constitutively active mitogen-activated protein kinase 6 or salicylate induces 3T3 L1 adipogenesis. J. Biol. Chem. 274:1999;356-373.
17. Englaro W., Berlotto C., Busca R., Brunet A., Pages G., Ortonne J., Ballotti R. Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation. J. Biol. Chem. 273:1998;9966-9970.
18. Finn G.J., Creaven B., Egan D. Study of the in vitro potential of natural and synthetic coumarin derivatives, using human normal and neoplastic skin cell lines. Mel. Res. 11:2001;461-467.
19. Finn G.J., Kenealy E., Creaven B.S., Egan D.A. In vitro cytotoxic potential and mechanism of action of selected coumarins, using human renal cell lines. Cancer Lett. 183:2002;61-68.
20. Finn G.J., Creaven B.S., Egan D.A. Investigation of intracellular signalling events mediating the mechanism of action of 7-hydroxyoumarin and 6-nitro-7-hydroxycoumarin in human renal cells. Cancer Lett. 2003;. (in press).
21. Flanagan R., Yonover P.M. Should radical nephrectomy be preformed in the face of surgically incurable disease. Curr. Opin. Urol. 10:2000;429-439.
22. Ghosh R., Ott A.M., Seetharam D., Slaga T.J., Kumanar A.P. Cell cycle block and apoptosis induction in a human melanoma cell line following treatment with 2-methoxyoestradiol: therapeutic implications? MEL Res. 13:2003;119-127.
23. Gobe G., Rubin M., Williams G., Sawczuki I., Buttyan R. Apoptosis and expression of Bcl-2, Bcl-XL and Bax in renal cell carcinomas. Cancer Investig. 20:2002;324-332.
24. Goroscpe M., Wang X., Holbrook N.J. Functional role of p21 during cellular response to genotoxic stress. Gene Expr. 7:1999;377-385.
25. Hagemann C., Blank J. The ups and downs of MEK kinase interactions. Cell. Signal. 13:2001;863-875.
26. Hanahan D., Weinberg R.A. The hallmarks of apoptosis. Cell. 100:2000;57-70.
27. Hoult J.R.S., Paya M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen. Pharmacol. 27:1996;713-722.
28. Hu Y., Chan E., Wang S.X., Li B. Activation of p38 mitogen-activated protein kinase is required for osteoblast differentiation. Endocrinology. 144:2003;2068-2074.
29. Jimenez-Orozco F.A., Lopz-Gonzalz J.S., Nieto-Rodriguez A., Velasco-Velazquez M.A., Molina-Guarneros J.A., Mendoza-Patino N., Garcia-Mondragon M.J., Elizalde-Galavan P., Leon-Cedeno F., Mandoki J.J. Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. Lung Cancer. 34:2001;185-194.
30. Kartner N., Denoyers S., Ottovian Y., Davidson N.E., Poirier G.G. Specific proteolytic cleavage of poly(ADP ribose) polymerase: an early indicator of chemotherapy induced apoptosis. Cancer Res. 53:1993;3976-3985.
31. Kelly V.P., Ellis E.M., Musno M.M., Chanas S.A., Moffat G.J., McLeod R., Judah D.J., Neal G.E., Hayes J.D. Chemoprevention of aflatoxin B1 hepatocarcinogenesis by coumarin, a natural benzopyrone that is a potent inducer of aflatoxin-B1-aldehyde reductase, the glutathione S-transferase A5 and P1nsubunits, and NADPH: quinone reductase in rat liver. Cancer Res. 60:2000;957-969.
32. Kirkiacharian S., Thuy T.D., Sicsic S., Bakhchinian R., Kurkjian R. Structure-activity relationships of some 3-substituted-4-hydroxycoumarins as HIV-1 protease inhibitors. Farmaco. 57:2002;703-708.
33. Laurin P., Klich M., Dupis-Hamelin C., Mauvais P., Lassaigne P., Bonnefoy A., Musicki B. Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B. Bioorganic Med. Chem. Letters. 9:1999;2079-2084.
34. Lu H.Q., Schmitz U., Niggemann B., Zanker K.S. Computer assisted molecular design for the determination of structure-activity relationships for chemotherapeutic agents. Ann. N.Y. Acad. Sci. 833:1997;147-153.
35. Marshall E.M., Riley L.K., Rhoades J., Eichnorm T., Jennings C.D., Cibule M., Thompson J. Effects of coumarin (1,2-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells and monocytes in patients with advanced malignancies. J. Biol. Response Modif. 8:1989;62-69.
36. Marshall E.M., Ryles M., Butler K., Weiss L. Treatment of advanced renal cell carcinoma (RCC) with coumarin and cimetidine: long-term follow-up of patients treated on a phase I trial. J. Cancer Res. Clin. Oncol. 120:1994;535-538.
37. Matsunago A., Hanawalt P.C. Histone H3 and heat shock protein GRP78 are selectively cross-linked to DNA by photoactivated gilvocarcin V in human fibroblasts. Cancer Res. 60:2000;3921-3926.
38. Nebreda A.R. p38 MAP kinases: beyond the stress responses. Trends biochem. sci. 25:2000;257-260.
39. Nunez R. DNA measurement and cell cycle analysis by flow cytometry. Curr. Issues Mol. Biol. 3:2001;67-70.
40. Oka H., Chatani Y., Hoshino R., Ogawa O., Kakehi Y., Terachi T., Okada Y., Kawaichi M., Kohno M., Yoshida O.Y. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 55:1995;4182-4187.
41. Ozaki I., Tani E., Ikemoto H., Kitagawa H., Fujikawa H. Activation of stress-activated protein kinase c-jun terminal kinase and p38 kinase in calphostin c induced apoptosis requires caspase-3-like proteases but is dispensable for cell death. J. Biol. Chem. 7:1999;5310-5317.
42. Sawafuji K., Miyakawa Y., Kizaki M., Ikeda Y. Cyclosporin A induces erythroid differentiation of K562 cells through p38 MAPK and ERK pathways. Am. J. Hematol. 72:2003;67-69.
43. She Q., Bode A., Ma W., Chen N.Y., Dong Z. Resveratrol induced activation of p38 and apoptosis is mediated by extra-cellular signal regulated protein kinases and p38 kinase. Cancer Res. 61:2001;1604-1610.
44. Takuwa N., Takuwa Y. Regulation of cell cycle molecules by the Ras effector system. Mol. Cell. Endocrinol. 177:2001;25-33.
45. Vuky J., Motzer R.J. Cytokine therapy in renal cell cancer. Urol. Oncol. 5:2000;249-257.
46. Wang C.J., Hsieh Y.J., Chu C., Lin Y., Tseng T.H. Inhibition of cell cycle progression in human leukemia HL-60 cells by esculetin. Cancer Lett. 183:2002;163-168.
47. Yu D., Suzuki M., Xie L., Morris-Natschke S.L., Lee K.H. Recent progress in the development of coumarin derivatives as potent anti-HIV agents. Med. Res. Rev. 23:2003;322-345.